CB(1) cannabinoid receptors and their associated proteins
- PMID: 20166926
- PMCID: PMC3179980
- DOI: 10.2174/092986710790980023
CB(1) cannabinoid receptors and their associated proteins
Abstract
CB1 receptors are G-protein coupled receptors (GPCRs) abundant in neurons, in which they modulate neurotransmission. The CB(1) receptor influence on memory and learning is well recognized, and disease states associated with CB(1) receptors are observed in addiction disorders, motor dysfunction, schizophrenia, and in bipolar, depression, and anxiety disorders. Beyond the brain, CB(1) receptors also function in liver and adipose tissues, vascular as well as cardiac tissue, reproductive tissues and bone. Signal transduction by CB(1) receptors occurs through interaction with Gi/o proteins to inhibit adenylyl cyclase, activate mitogen-activated protein kinases (MAPK), inhibit voltage-gated Ca(2+) channels, activate K(+) currents (K(ir)), and influence Nitric Oxide (NO) signaling. CB(1) receptors are observed in internal organelles as well as plasma membrane. beta-Arrestins, adaptor protein AP-3, and G-protein receptor-associated sorting protein 1 (GASP1) modulate cellular trafficking. Cannabinoid Receptor Interacting Protein1a (CRIP1a) is an accessory protein whose function has not been delineated. Factor Associated with Neutral sphingomyelinase (FAN) regulates ceramide signaling. Such diversity in cellular signaling and modulation by interacting proteins suggests that agonists and allosteric modulators could be developed to specifically regulate unique, cell type-specific responses.
Conflict of interest statement
Conflict of Interest: The authors have not received financial contributions to the work being reported, and do not report any conflict of interest. ACH has served on the speaker’s bureau for Sanofi-Aventis within the last three years.
Similar articles
-
Signal transduction of the CB1 cannabinoid receptor.J Mol Endocrinol. 2010 Feb;44(2):75-85. doi: 10.1677/JME-08-0190. Epub 2009 Jul 20. J Mol Endocrinol. 2010. PMID: 19620237 Review.
-
Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery?Br J Pharmacol. 2010 Jun;160(3):454-66. doi: 10.1111/j.1476-5381.2010.00777.x. Br J Pharmacol. 2010. PMID: 20590557 Free PMC article. Review.
-
Mechanisms underlying cannabinoid inhibition of presynaptic Ca2+ influx at parallel fibre synapses of the rat cerebellum.J Physiol. 2004 May 15;557(Pt 1):159-74. doi: 10.1113/jphysiol.2004.063263. Epub 2004 Mar 19. J Physiol. 2004. PMID: 15034129 Free PMC article.
-
CB(1) cannabinoid receptor-G protein association: a possible mechanism for differential signaling.Chem Phys Lipids. 2002 Dec 31;121(1-2):91-109. doi: 10.1016/s0009-3084(02)00153-6. Chem Phys Lipids. 2002. PMID: 12505694 Review.
-
Cannabinoid receptor interacting protein (CRIP1a) attenuates CB1R signaling in neuronal cells.Cell Signal. 2015 Mar;27(3):716-726. doi: 10.1016/j.cellsig.2014.11.006. Epub 2014 Nov 17. Cell Signal. 2015. PMID: 25446256 Free PMC article.
Cited by
-
The Neuroprotective Effect of NEUROMIDE, a Compound Bioidentical to Commensal Bacteria Metabolites.Life (Basel). 2022 Sep 30;12(10):1529. doi: 10.3390/life12101529. Life (Basel). 2022. PMID: 36294963 Free PMC article.
-
Roadmap for the expression of canonical and extended endocannabinoid system receptors and metabolic enzymes in peripheral organs of preclinical animal models.Physiol Rep. 2024 Feb;12(4):e15947. doi: 10.14814/phy2.15947. Physiol Rep. 2024. PMID: 38408761 Free PMC article.
-
Cannabinoid receptor interacting protein suppresses agonist-driven CB1 receptor internalization and regulates receptor replenishment in an agonist-biased manner.J Neurochem. 2016 Nov;139(3):396-407. doi: 10.1111/jnc.13767. Epub 2016 Sep 26. J Neurochem. 2016. PMID: 27513693 Free PMC article.
-
Leveraging allostery to improve G protein-coupled receptor (GPCR)-directed therapeutics: cannabinoid receptor 1 as discovery target.Expert Opin Drug Discov. 2016 Dec;11(12):1223-1237. doi: 10.1080/17460441.2016.1245289. Epub 2016 Oct 21. Expert Opin Drug Discov. 2016. PMID: 27712124 Free PMC article. Review.
-
Cannabinoid Receptor 1 Inhibition in Chronic Kidney Disease: A New Therapeutic Toolbox.Front Endocrinol (Lausanne). 2021 Jul 7;12:720734. doi: 10.3389/fendo.2021.720734. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34305821 Free PMC article. Review.
References
-
- Howlett AC, Bidaut-Russell M, Devane WA, Melvin LS, Johnson MR, Herkenham M. The cannabinoid receptor: biochemical, anatomical and behavioral characterization. Trends Neurosci. 1990;13:420–423. - PubMed
-
- Johnson MR, Melvin LS, Althuis TH, Bindra JS, Harbert CA, Milne GM, Weissman A. Selective and potent analgetics derived from cannabinoids. J Clin Pharmacol. 1981;21:271S–282S. - PubMed
-
- Berlach DM, Shir Y, Ware MA. Experience with the synthetic cannabinoid nabilone in chronic noncancer pain. Pain Med. 2006;7:25–29. - PubMed
-
- Jain AK, Ryan JR, McMahon FG, Smith G. Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. J Clin Pharmacol. 1981;21:320S–326S. - PubMed
-
- Young AM, Katz JL, Woods JH. Behavioral effects of levonantradol and nantradol in the rhesus monkey. J Clin Pharmacol. 1981;21:348S–360S. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous